

Special Issue

Actions of Small Molecules on Varying Type of Membrane Ion Channels 2.0

Message from the Guest Editor

Ion channels, viewed as enigmatic proteins, are recognized to select ions to pass through the cell membrane in a wide variety of cells. Changes in these types of ion channels can act to perturb the functional activities of Na⁺, Ca²⁺, and K⁺ channels, and, therefore, play essential roles in numerous fundamental physiological functions, such as controlling membrane excitability, generating and shaping action potentials, regulating cell volume, and regulating epithelial secretion. Recent progress in the biophysical or pharmacological characterization of ion channels potentially modified by different small molecules (i.e., ion channel modulators) has demonstrated the fundamental importance of ion channels in physiology, pathophysiology, pharmacology, and various pathologic disorders. However, the potential of these small-molecule modulators as targets for novel and efficacious therapeutics is still incompletely understood. It is hoped that this Special Issue in *Biomedicines* will provide the current understanding of several intriguing small molecules which can effectively perturb the amplitude, gating kinetics, and voltage-dependent hysteresis of membrane ionic currents.

Guest Editor

Prof. Dr. Sheng-Nan Wu
Department Physiology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/136271

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).